Clinical Psychiatry News - Abilify available as oral solution
An oral solution formulation of Abilify (aripiprazole) is now available. Abilify is indicated for the treatment of schizophrenia and for the treatment of acute manic and mixed episodes associated with bipolar disorder. For more information, contact Otsuka America Pharmaceutical Inc., by visiting www.abilify.com, or by calling 800-321-1335.
Related Results
Abilify approvalAbilify approvalNew AbilifyNew ABILIFY formulationAbilify wins clearance
COPYRIGHT 2005 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
